MarketPulse

ophthalmic pharmaceuticals

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Tarsus Pharmaceuticals Accelerates XDEMVY Growth, Eyes $670M-$700M 2026 Sales

Tarsus reports Q1 2026 XDEMVY sales exceeding $145M, up 85% YoY, while maintaining full-year guidance of $670M-$700M.
TARSinvestor conferencesQ1 2026 earnings
The Motley FoolThe Motley Fool··Andy Gould

Major Shareholder Trims $7.8M Harrow Stake, Signals Profit-Taking Over Retreat

Opaleye Management sold $7.8M in $HARR shares while retaining 10% stake, suggesting tactical rebalancing rather than loss of confidence in ophthalmic pharma company.
HROWearnings missportfolio rebalancing